BioCentury
ARTICLE | Clinical News

DPX-Survivac: Phase I/II data

July 2, 2012 7:00 AM UTC

Data from the first cohort (n=3) of the Phase I portion of a Phase I/II trial showed that 0.5 mL subcutaneous DPX-Survivac every 3 weeks for 6 weeks was well tolerated with no serious adverse events r...